Evidence map›Paper›PMID 35274388›Full record

ReviewHead & neck2022

American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.

David C Shonka, Alan Ho, Ashish V Chintakuntlawar, Jessica L Geiger, Jong C Park, Nagashree Seetharamu, Sina Jasim, Amr H Abdelhamid Ahmed, Keith C Bible, Marcia S Brose and 21 more

Open access · greenAbstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Head & neck, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
14.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 18 institutions in 3 countries.

David C ShonkaDepartment of Otolaryngology - Head and Neck Surgery, University of Virginia, Charlottesville, Virginia, USA.ORCID 0000-0002-8893-9703
Alan HoDepartment of Hematology and Medical Oncology, Solid Tumor Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ashish V ChintakuntlawarDivision of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Jessica L GeigerDepartment of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.
Jong C ParkDepartment of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-1052-0734
Nagashree SeetharamuDivision of Hematology-Oncology, Donald and Barbara Zucker School of Medicine at Hofstra University, New Hyde Park, New York, USA.
Sina JasimDivision of Endocrinology, Metabolism and Lipid Research, Department of Internal Medicine, School of Medicine, Washington University in St. Louis, Saint Louis, Missouri, USA.
Amr H Abdelhamid AhmedDepartment of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.ORCID 0000-0001-5611-5833
Keith C BibleDivision of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Marcia S BroseAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Maria E CabanillasDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-5124-1811
Kirsten DabekaussenDepartment of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Louise DaviesDepartment of Surgery, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.ORCID 0000-0001-5581-2813
Dora Dias-SantagataDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
James A FaginEndocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
William C FaquinDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Ronald A GhosseinDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Raj K GopalDepartment of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Akira MiyauchiDepartment of Surgery, Kuma Hospital, Kobe, Japan.
Yuri E NikiforovDepartment of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Matthew D RingelDivision of Endocrinology, Diabetes, and Metabolism, The Ohio State University Medical Center, Columbus, Ohio, USA.
Bruce RobinsonNorthern Clinical School, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Mabel M RyderDivision of Endocrinology, Diabetes, Metabolism, & Nutrition, Mayo Clinic, Rochester, Minnesota, USA.
Eric J ShermanHead and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Peter M SadowDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Jennifer J ShinDepartment of Otolaryngology - Head and Neck Surgery, Center for Surgery and Public Health, Harvard Medical School, Boston, Massachusetts, USA.
Brendan C StackDepartment of Otolaryngology - Head and Neck Surgery, Southern Illinois University School of Medicine, Springfield, Illinois, USA.
R Michael TuttleEndocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Lori J WirthDepartment of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Mark E ZafereoDepartment of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Gregory W RandolphDepartment of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.
Memorial Sloan Kettering Cancer Center · USHarvard University · USMassachusetts General Hospital · USMayo Clinic · USMassachusetts Eye and Ear Infirmary · USThe University of Texas MD Anderson Cancer Center · USBrigham and Women's Hospital · USCleveland Clinic · USDartmouth College · USHofstra University · USKuma Hospital · JPSouthern Illinois University School of Medicine · USThe Ohio State University Wexner Medical Center · USThe University of Sydney · AUUniversity of Pennsylvania · USUniversity of Pittsburgh · USUniversity of Virginia · USWashington University in St. Louis · US

Funding

Strategies to Overcome Immune Resistance in Head and Neck CancersP01CA240239 · NCI · YALE UNIVERSITY · PI PAI, SARA ISABEL · 2019 to 2023
$8.4M
NCI NIH HHS P01 CA240239
6 · The paper itself

Abstract

backgroundThe development of systemic treatment options leveraging the molecular landscape of advanced thyroid cancer is a burgeoning field. This is a multidisciplinary evidence-based statement on the definition of advanced thyroid cancer and its targeted systemic treatment.

methodsAn expert panel was assembled, a literature review was conducted, and best practice statements were developed. The modified Delphi method was applied to assess the degree of consensus for the statements developed by the author panel.

resultsA review of the current understanding of thyroid oncogenesis at a molecular level is presented and characteristics of advanced thyroid cancer are defined. Twenty statements in topics including the multidisciplinary management, molecular evaluation, and targeted systemic treatment of advanced thyroid cancer are provided.

conclusionsWith the growth in targeted treatment options for thyroid cancer, a consensus definition of advanced disease and statements regarding the utility of molecular testing and available targeted systemic therapy is warranted.

Indexed as

Thyroid NeoplasmsConsensusHumansMedical OncologyThyroid Function TestsUnited Statesadvanced thyroid cancerconsensus statementmolecular testingsystemic therapytargeted treatment

Identifiers

PMID35274388
PMCPMC9332138
OpenAlexW4221035002

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.